Laminaran

Research use only, not for human use.

Laminaran is a β-1,3-glucan isolated from brown algae, often serving as a typical ligand for Dectin-1.

Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Laminaran (100-800 μg/mL; 24 hours) is not cytotoxic against normal epidermal cells JB6 Cl41 and human melanoma cells SK-MEL-28, the percentage of inhibition of living cells number is less than 15 % at concentrations range up to 800 μg/mL after 24 h of treatment.Laminaran (200 μg/mL; 24-72 hours)does not cause any growth inhibition of SK-MEL-28 cells after 24 and 48 h of treatment, but decreases cells proliferation by 36 % after 72 h of treatment.Laminaran (25-50 μg/mL; 24 hours) at low concentration does not influence the phosphorylation of c-Raf (Ser259), ERK1/2 (Tyr202/Tyr204), and MEK1/2 (Ser 221) kinases as well as total expression level of investigated proteins. But decreases p-MEK, p-ERK1/2 at 50 μg/mL.Cell Viability Assay Cell Line:JB6 Cl41 and SK-MEL-28 cells Concentration:100, 200, 400, and 800 μg/mL Incubation Time:24 hours Result:Showed no cytotoxic against normal epidermal cells JB6 Cl41 and human melanoma cells SK-MEL-28.Cell Proliferation Assay Cell Line:SK-MEL-28 cells Concentration:200 μg/mL Incubation Time: 24 hours Result:Decreased cell proliferation at 72 hours.Western Blot Analysis Cell Line:SK-MEL-28 cells Concentration:25 μg/mL; 50 μg/mL Incubation Time:24 hours Result:Inhibited phosphorylation of c-Raf, MEK1/2, and ERK1/2 kinases.

Laminaran (intravenous injection; 12.5, 25, and 50 mg/kg; 21 days) and OVA (50 μg) combination significanly decreases the tumor masses when it compares with the PBS-, OVA-, and laminarin-treated mice.Animal Model:C57BL/6 mice injected?s.c. with B16-OVA cells Dosage:12.5, 25, and 50 mg/kg; 21 days Administration:Intravenous injection Result:Prevented B16-OVA tumor growth by inducing Ag-specific immune responses.

——

Others

Other Targets

Others

——

——

9008-22-4

521.469

C18H35O16

>98% (HPLC)

In Vitro:?H2O : 16.67 mg/mL (Ultrasonic)

OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@@H](O)O[C@H](CO)[C@H]3O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years